Merck Oncology Strategy: With First-Line Lung Data, A New Day Dawns For Keytruda

Merck claims to have the broadest clinical development program for an anti-PD-1/L1 drug, with more than 270 trials under way testing Keytruda in 30 tumor types and 100 combinations.